Prostate Cancer - Results from #1700

Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial. December 1, 2023

Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer. December 1, 2023

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617. December 1, 2023

CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer. December 1, 2023

Social Drivers of Cancer Risk and Outcomes Among African American Men. December 1, 2023

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer. December 1, 2023

POSTER: Phase 1/2 Trial of Oral EPI-7386 (masofaniten) in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects mCRPC: Current Phase 1 (P1) Results November 30, 2023

Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis. November 30, 2023

Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence. November 30, 2023

Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank. November 30, 2023

Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer. November 30, 2023

Differential Impact of SPOP Mutation in Prostate and Endometrial Cancers. November 30, 2023

Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort November 29, 2023

Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features? November 29, 2023

Delphi consensus project on prostate-specific membrane antigen (PSMA)-targeted surgery-outcomes from an international multidisciplinary panel. November 29, 2023

Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry. November 29, 2023

Linking African ancestral substructure to prostate cancer health disparities. November 29, 2023

Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8+ T cell. November 29, 2023

Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. November 29, 2023

A novel intronic circular RNA circFGFR1int2 up-regulates FGFR1 by recruiting transcriptional activators P65/FUS and suppressing miR-4687-5p to promote prostate cancer progression. November 29, 2023

Page 86 of 1435